ABBOTT, DHARMACON INC TO DEVELOP NEW THERAPEUTIC AGENTS

Abbott and Dharmacon Inc. has announced that a collaboration to develop new therapeutic agents based on a gene silencing technology of RNA interference (RNAi). The research could extend drug discovery efforts for the two companies into disease targets, where traditional discovery technologies have not been successful.

PharmaBiz (http://pharmabiz.com/article/detnews.asp?articleid=34149)